GLP1a Drugs are Great But Unlikely to Treat COVID-19 Infection
Sensible Medicine
SEPTEMBER 2, 2024
First a review of the main trial then to the new paper in the Journal of the American College of Cardiology. SELECT Trial The SELECT trial was the first to show that the glucagon-like-peptide-1 receptor agonist (GLP1) semaglutide could actually modify cardiovascular disease. The discovery of another disease-modifying agent for heart disease is a breakthrough.
Let's personalize your content